Expansion into post-marketing drug development and differentiation
First written in FY2016. 17 of 33 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026-H1.
Linical moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Reframed".
- FY2026-H1ReframedAnnual report
「The Group previously had two reportable segments, the CRO business and the drug development support business, but changed to a single reportable segment, the CRO business, from the current interim consolidated accounting period. This change followed a review of the reportable segments in connection with the organizational changes implemented in April 2025, from the perspectives of the Board of Directors’ decisions on the allocation of management resources and performance evaluation. The Group determined that a single CRO business segment would more appropriately reflect its decision-making process.」
The Group changed from the former two segments, the CRO business and the drug development support business, to a single CRO business segment following the organizational changes in April 2025. The former arrangement of disclosing the drug development support business as an independent segment has changed to a single-segment structure that reflects the decision-making process. - FY2025-H1Lower revenue and operating loss in the drug development support businessAnnual report
「The Group’s drug development support business posted revenue of ¥270 million, down 29.0% year on year, and an operating loss of ¥24 million, compared with operating profit of ¥109 million in the same period of the previous year, resulting in lower revenue and profit year on year.」
Revenue in the drug development support business declined 29.0%, while operating profit turned from a profit in the same period of the previous year to an operating loss of ¥24 million. - FY2024Full-Year Revenue and Profit DeclineAnnual report
「The Group’s drug development support business posted revenue of ¥760 million, down 10.2% year on year, and operating profit of ¥148 million, down 6.0%, resulting in lower revenue and profit.」
The drug development support business did not recover from the lower revenue and profit posted in the previous fiscal year, with full-year revenue down 10.2% and operating profit down 6.0%. - FY2024-Q3Continued lower revenue and profit (wider decline in profit)Annual report
「The Group’s drug development support business posted revenue of ¥566 million, down 11.9% year on year, and operating profit of ¥107 million, down 53.6%, resulting in lower revenue and profit year on year.」
The drug development support business continued to post lower revenue and profit, with revenue down 11.9% and operating profit down 53.6%. The decline in operating profit widened from a 33.4% decline in revenue and a 15.5% decline in operating profit in the previous quarter. - FY2024-Q2Lower revenue and profit continuedAnnual report
「The Group’s drug development support business posted revenue of ¥381 million, down 15.5% year on year, and operating profit of ¥109 million, down 33.4%, resulting in lower revenue and profit year on year.」
The drug development support business posted declines of 15.5% in revenue and 33.4% in operating profit year on year, continuing its trend of lower revenue and profit. - FY2024-Q1Lower sales and lower operating incomeAnnual report
「② Drug development support business The Group’s drug development support business posted revenue of ¥189 million, down 23.4% year on year, and operating profit of ¥37 million, down 52.4%, resulting in lower revenue and profit.」
The drug development support business shifted from higher revenue and profit in the same period of the previous year to lower revenue and profit, with revenue down 23.4% and operating profit down 52.4%. - FY2023-Q3Lower revenue, higher profit (profit broadly flat)Annual report
「The Group’s drug development support business posted revenue of ¥642 million, down 9.8% year on year, and operating profit of ¥232 million, up 0.1% year on year, resulting in lower revenue but higher profit year on year.」
The drug development support business shifted from higher revenue and profit in the same period of the previous year to lower cumulative third-quarter revenue, down 9.8%, and broadly flat operating profit, up 0.1%. - FY2023-Q2AdvancedAnnual report
「The Group’s drug development support business posted revenue of ¥451 million, up 17.7% year on year, and operating profit of ¥164 million, up 30.1%, resulting in higher revenue and profit year on year.」
The drug development support business posted increases of 17.7% in revenue and 30.1% in operating profit year on year, resulting in higher revenue and profit. - FY2023-Q1AdvancedAnnual report
「② Drug development support business The Group’s drug development support business posted revenue of ¥247 million, up 28.6% year on year, and operating profit of ¥78 million, up 94.2%, resulting in higher revenue and profit.」
The drug development support business posted increases of 28.6% in revenue and 94.2% in operating profit year on year, resulting in higher revenue and profit. - FY2022-Q3Lower revenue, higher profit (recovery in orders)Annual report
「In the Group’s drug development support business, order acquisition was sluggish in the previous fiscal year after pharmaceutical companies revised their development plans due to COVID-19 and the narrowing of development projects. In the current fiscal year, however, orders were secured steadily, and costs incurred were controlled. As a result, revenue was ¥711 million, down 4.7% year on year, while operating profit was ¥232 million, up 25.7%, resulting in lower revenue but higher profit year on year.」
Orders in the drug development support business were secured steadily, and operating profit increased 25.7%, partly because costs incurred were controlled. Revenue, however, declined 4.7%, resulting in lower revenue but higher profit. - FY2022-Q2Lower revenue and profit continuedAnnual report
「The Group’s drug development support business was affected by sluggish orders secured in the previous fiscal year for revenue in the current fiscal year, following revisions to pharmaceutical companies’ development plans due to COVID-19 and the narrowing of development projects. In addition, progress on some projects was delayed in the second quarter, slowing the completion of contracted projects. As a result, revenue was ¥384 million, down 26.6% year on year, and operating profit was ¥126 million, down 17.4%, resulting in lower revenue and profit year on year.」
The drug development support business posted lower revenue and profit, with revenue down 26.6% and operating profit down 17.4%, as sluggish order acquisition was compounded by delays in the progress of some projects, slowing the completion of contracted projects. - FY2022-Q1Lower revenue, with profit maintainedAnnual report
「The Group’s drug development support business posted lower revenue because orders secured in the previous fiscal year were sluggish, reflecting the impact of COVID-19 and revisions to pharmaceutical companies’ development plans, including the narrowing of development projects. On the earnings front, however, profit was maintained at approximately the same level through measures including control of personnel expenses and other costs. As a result, revenue was ¥192 million, down 25.5% year on year, and operating profit was ¥40 million, down 0.5%.」
Revenue in the drug development support business declined 25.5% as orders secured in the previous fiscal year were sluggish, while operating profit was ¥40 million, with the decline limited to 0.5% year on year through control of personnel expenses and other costs. - FY2021Full-year revenue and profit declineAnnual report
「The Group’s drug development support business posted lower revenue and profit for the reasons described in the overview of the consolidated fiscal year. As a result, revenue was ¥949 million, down 8.0% year on year, and operating profit was ¥247 million, down 32.8% year on year.」
The drug development support business shifted from higher revenue and profit in the previous fiscal year to lower full-year revenue and profit, with revenue down 8.0% and operating profit down 32.8%. - FY2021-Q3Higher revenue and lower earningsAnnual report
「In the Group’s drug development support business, orders increased, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue. As a result, revenue was ¥747 million, up 1.8% year on year, and operating profit was ¥286 million, down 5.0%.」
Revenue in the drug development support business increased on higher orders for clinical research projects, while operating profit declined 5.0% year on year. - FY2021-Q2AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥523 million, up 18.5% year on year, and operating profit was ¥218 million, up 31.0%.」
The drug development support business posted an 18.5% increase in revenue and a 31.0% increase in operating profit on orders for clinical research projects. - FY2021-Q1AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥259 million, up 42.4% year on year, and operating profit was ¥79 million, up 164.2%.」
The utilization rate of personnel increased on orders for clinical research projects in the drug development support business, resulting in a 42.4% increase in revenue and a 164.2% increase in operating profit. - FY2020AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥1,032 million, up 8.2% year on year, and operating profit was ¥427 million, up 36.2%.」
The drug development support business posted full-year increases of 8.2% in revenue and 36.2% in operating profit as the utilization rate of personnel increased on orders for clinical research projects. - FY2020-Q3Declining revenue and higher profitAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs. Although revenue declined, the business contributed to profit. As a result, revenue was ¥733 million, down 2.9% year on year, and operating profit was ¥301 million, up 12.1%.」
The utilization rate of personnel increased on orders for clinical research projects in the drug development support business. Revenue declined 2.9%, while operating profit increased 12.1%. - FY2020-Q2Continued lower revenue and profit due to the gap between the completion of existing projects and the start of new projects (narrower declines in revenue and profit)Annual report
「The Group’s drug development support business remained between the completion of existing projects and the start of new projects. In addition, a large project began in the previous fiscal year and generated relatively substantial revenue. As a result, revenue was ¥441 million, down 10.9% year on year, and operating profit was ¥166 million, down 8.3%.」
The gap between the completion of existing projects and the start of new projects continued in the drug development support business, resulting in a 10.9% decline in revenue and an 8.3% decline in operating profit. The reversal of the large project that began in the same period of the previous year was also cited. - FY2020-Q1Lower revenue and profit due to the gap between the completion of existing projects and the start of new projectsAnnual report
「The Group’s drug development support business was in a period between the completion of existing projects and the start of new projects. In addition, a large project began in the first quarter of the previous fiscal year and generated relatively substantial revenue. As a result, revenue was ¥181 million, down 31.9% year on year, and operating profit was ¥30 million, down 63.8%.」
The drug development support business posted a 31.9% decline in revenue and a 63.8% decline in operating profit due to the gap between the completion of existing projects and the start of new projects, as well as the absence of the large project recorded in the same period of the previous year. - FY2019AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥954 million, up 5.0% year on year, and operating profit was ¥313 million, up 9.0%.」
The drug development support business posted full-year increases of 5.0% in revenue and 9.0% in operating profit as the utilization rate of personnel increased on orders for clinical research projects following the launch of new drugs. - FY2019-Q3AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥755 million, up 15.9% year on year, and operating profit was ¥269 million, up 33.5%.」
The utilization rate of personnel increased as orders for clinical research projects following the launch of new drugs grew, resulting in a 15.9% increase in revenue and a 33.5% increase in operating profit in the drug development support business. - FY2019-Q2AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the launch of new drugs, contributing to revenue and profit. As a result, revenue was ¥495 million, up 16.5% year on year, and operating profit was ¥182 million, up 28.3%.」
Driven by orders for clinical research projects following the launch of new drugs, the drug development support business posted a 16.5% increase in revenue and a 28.3% increase in operating profit for the first two quarters cumulatively. - FY2019-Q1AdvancedAnnual report
「In the Group’s drug development support business, the utilization rate of personnel increased as orders grew, mainly for projects involving clinical research following the sale of new drugs, contributing to revenue and profit. As a result, revenue was ¥266 million, up 22.4% year on year, and operating profit was ¥83 million, up 47.9%.」
The utilization rate of personnel increased as orders for clinical research projects following the sale of new drugs grew, resulting in a 22.4% increase in revenue and a 47.9% increase in operating profit in the drug development support business. - FY2018AdvancedAnnual report
「The business contributed to revenue as orders increased, mainly for company-sponsored clinical research, including Japan-led international clinical research in Japan, Taiwan and South Korea. On the earnings front, however, revenue growth fell short of initial expectations, and the increase in personnel expenses from upfront investment in human resources and costs associated with relocating the Tokyo office could not be fully absorbed, resulting in lower profit. As a result, revenue was ¥908 million, up 12.7% year on year, and operating profit was ¥288 million, down 1.7% year on year.」
Revenue in the drug development support business increased 12.7% as orders for international clinical research in Japan, Taiwan and South Korea increased, while operating profit declined 1.7%. - FY2018-Q3AdvancedAnnual report
「The Group’s drug development support business contributed to revenue as orders increased, mainly for company-sponsored clinical research, including Japan-led international clinical research in Japan, Taiwan and South Korea. On the earnings front, however, revenue growth fell short of initial expectations, and the increase in personnel expenses from upfront investment in human resources and costs associated with relocating the Tokyo office could not be fully absorbed, resulting in lower profit. As a result, revenue was ¥651 million, up 14.3% year on year, and operating profit was ¥201 million, down 1.2% year on year.」
Revenue in the drug development support business increased 14.3% as orders increased for company-sponsored clinical research projects, including international clinical research in Japan, Taiwan and South Korea. Operating profit, however, declined 1.2%. - FY2018-Q2AdvancedAnnual report
「In the Group’s post-marketing drug development business, staff utilization increased as a result of accepting projects centered on clinical research after the launch of new drugs, contributing to revenue and earnings. Net sales were ¥425 million, up 27.9% year on year, and operating income was ¥141 million, up 23.6%.」
Revenue in the drug development support business increased 27.9% and operating profit increased 23.6%, driven by orders for clinical research projects following the launch of new drugs. - FY2018-Q1AdvancedAnnual report
「In the Group’s post-marketing drug development business, staff utilization increased as a result of accepting projects centered on clinical research after the launch of new drugs, contributing to revenue and earnings. Net sales were ¥218 million, up 42.8% year on year, and operating income was ¥56 million, up 76.6%.」
Acceptance of clinical research projects after the launch of new drugs increased staff utilization, resulting in revenue growth of 42.8% and operating income growth of 76.6% in the post-marketing drug development business. - FY2017AdvancedAnnual report
「In the Group’s post-marketing drug development business, new contracts for company-sponsored clinical research projects after the launch of new drugs increased, resulting in substantial business growth and contributing to revenue and earnings. Net sales were ¥806 million, up 45.8% year on year, and operating income was ¥293 million, up 40.7%.」
An increase in new contracts for company-sponsored clinical research projects resulted in full-year revenue growth of 45.8% and operating income growth of 40.7% in the post-marketing drug development business. - FY2017-Q3AdvancedAnnual report
「In the Group’s post-marketing drug development business, new contracts for company-sponsored clinical research projects after the launch of new drugs increased, contributing to a substantial improvement in performance and to revenue and earnings. Net sales were ¥570 million, up 43.9% year on year, and operating income was ¥204 million, up 39.1%.」
An increase in new contracts for company-sponsored clinical research projects resulted in revenue and operating income in the post-marketing drug development business exceeding the prior-year period, with the growth rates also stated. - FY2017-Q2AdvancedAnnual report
「In the Group’s post-marketing drug development business, new contracts for company-sponsored clinical research projects after the launch of new drugs increased, contributing to revenue and earnings. Net sales were ¥332 million, up 31.4% year on year, and operating income was ¥114 million, up 5.2%.」
New contracts for company-sponsored clinical research projects increased, resulting in revenue growth of 31.4% and operating income growth of 5.2% in the post-marketing drug development business. - FY2017-Q1AdvancedAnnual report
「In the Group’s post-marketing drug development business, staff utilization increased as a result of accepting projects centered on clinical research after the launch of new drugs, contributing to revenue and earnings. Net sales were ¥152 million, up 48.8% year on year, and operating income was ¥31 million, up 44.8%.」
Acceptance of clinical research projects increased staff utilization, and revenue and operating income in the post-marketing drug development business exceeded the prior-year period. - FY2016First statedAnnual report
「The Group operates a post-marketing drug development business in the post-marketing market downstream of the pharmaceutical development services undertaken in its CRO business, accepting multiple projects including sales planning and clinical research.」
The Group operates a post-marketing drug development business downstream of its CRO business, including sales planning and clinical research.